{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:26:29Z","timestamp":1784031989784,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11523-022-00915-9","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T09:19:14Z","timestamp":1663751954000},"page":"675-682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study"],"prefix":"10.1007","volume":"17","author":[{"given":"Assya","family":"Akli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Fallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Rousseau-Bussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gounant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Friard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Tr\u00e9daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Dujon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Duchemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Giroux-Leprieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"issue":"10026","key":"915_CR1","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","volume":"387","author":"F Barlesi","year":"2016","unstructured":"Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415\u201326.","journal-title":"Lancet"},{"issue":"2","key":"915_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, et al. Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"1","key":"915_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","journal-title":"N Engl J Med"},{"issue":"6","key":"915_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560\u20132.","journal-title":"Nat Med"},{"issue":"19","key":"915_CR5","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-15-1915","volume":"22","author":"S Ortiz-Cuaran","year":"2016","unstructured":"Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res. 2016;22(19):4837\u201347.","journal-title":"Clin Cancer Res"},{"key":"915_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","volume":"137","author":"C Mehlman","year":"2019","unstructured":"Mehlman C, Cadranel J, Rousseau-Bussac G, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. 2019;137:149\u201356.","journal-title":"Lung Cancer"},{"key":"915_CR7","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2009;79."},{"issue":"25","key":"915_CR8","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.19.03123","volume":"38","author":"AJ Piper-Vallillo","year":"2020","unstructured":"Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review. J Clin Oncol. 2020;38(25):2926\u201336.","journal-title":"J Clin Oncol"},{"issue":"2","key":"915_CR9","volume":"1","author":"D Enrico","year":"2020","unstructured":"Enrico D, Lacroix L, Chen J, Rouleau E, et al. Oncogenic fusions may be frequently present at resistance of EGFR tyrosine kinase inhibitors in patients with NSCLC: a brief report. JTO Clin Res Rep. 2020;1(2): 100023.","journal-title":"JTO Clin Res Rep."},{"issue":"7","key":"915_CR10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","volume":"8","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836\u201349.","journal-title":"Cancer Discov"},{"issue":"4","key":"915_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","volume":"31","author":"GR Oxnard","year":"2020","unstructured":"Oxnard GR, Yang JCH, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31(4):507\u201316.","journal-title":"Ann Oncol"},{"issue":"30","key":"915_CR12","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"MD Keunchil Park","year":"2021","unstructured":"Keunchil Park MD, et al. Amivantamab in EGFR Exon 20 insertion-mutated non\u2013small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391\u2013402.","journal-title":"J Clin Oncol"},{"issue":"6","key":"915_CR13","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.drudis.2021.02.005","volume":"26","author":"SK Tripathi","year":"2021","unstructured":"Tripathi SK, Biswal BK. Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma. Drug Discov Today. 2021;26(6):1466\u201372.","journal-title":"Drug Discov Today"},{"issue":"7605","key":"915_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","volume":"534","author":"Y Jia","year":"2016","unstructured":"Jia Y, Yun CH, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129\u201332.","journal-title":"Nature"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00915-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-022-00915-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00915-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T09:40:10Z","timestamp":1669196410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-022-00915-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1007\/s11523-022-00915-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"26 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Assya Akli, Sylvie Friard, Jean Tr\u00e9daniel, and C\u00e9cile Dujon declare they have no conflicts of interest that might be relevant to the contents of this manuscript. Nicolas Girard has received research grants from Boehringer Ingelheim, AstraZeneca, Pfizer, and Roche. Vincent Fallet has received research grants from MSD, Novartis, Roche, Sanofi and Boehringer Ingelheim; and personal fees and non-financial support from AstraZeneca, BMS, Takeda, Jansen, and Pfizer, all outside the submitted work. Gaelle Rousseau Bussac has received research grants, or funding for participation in congresses, research activities, training activities, and participation in expert groups, from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen-Cilag, Lilly, Mundipharma, MSD, Novartis, Pfizer, Roche, and Takeda. Val\u00e9rie Gounant has received research grants from MSD, Chugai, Novartis, and Boehringer Ingelheim; personal fees and non-financial support from AstraZeneca, BMS, Takeda, and Pfizer; and grants, personal fees, and non-financial support from Roche, all outside the submitted work. Marie Wislez has received research grants from AstraZeneca. Boris Duchemann has received research grants from BMS, Roche, Pfizer, AstraZeneca, Chiesi, Amgen, and Lilly, and reports congress fees from AstraZeneca, Pfizer, and Oxyvie. \u00c9tienne Giroux-Leprieur has received research grants from MSD, Novartis, Roche, Sanofi, Boehringer Ingelheim, AstraZeneca, BMS, Takeda, Jansen, and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This retrospective study was approved by the Institutional Review Board (CEPRO) of the Soci\u00e9t\u00e9 de Pneumologie de Langue Fran\u00e7aise (SPLF) on 1 March 2019.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients consented to participate in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conception of the study: AA, EGL; Collection of the data: AA, NG, VF, GRB, VG, SF, JT, CD,\nMW, BD, EGL; Analyses of the data: AA, EGL; Writing of the manuscript: AA, EGL; review of the manuscript: AA,\nNG, VF, GRB, VG, SF, JT, CD, MW, BD, EGL.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}